Status:
RECRUITING
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
Lead Sponsor:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Conditions:
Solid Cancers
Eligibility:
All Genders
Brief Summary
This project aims to monitor the innocuity/safety profile of cyclotron-produced \[68Ga\]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label ...
Detailed Description
In developed countries such as Canada, prostate cancers are the most frequently diagnosed and the third deadliest cancer among men. Early detection and management of low-stage prostate cancer leads to...
Eligibility Criteria
Inclusion
- Clinical requisition for a 68Ga-PSMA-617 PET/CT signed by a referring doctor;
- Patients with suspected, proven or prior tumor expressing PSMA;
- Informed consent by patient.
Exclusion
- Patient refusal to participate;
- Prior severe anaphylactic reaction to 68Ga-PSMA-617 .
Key Trial Info
Start Date :
January 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05228106
Start Date
January 21 2022
End Date
January 31 2027
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHUS
Sherbrooke, Quebec, Canada, J1H5N4